



Host-Microbiome Crosstalk in Cardiometabolic Diseases

Guest Editor:

Dr. Philippe Gerard

Micalis Institute, INRAE,
AgroParisTech, Université Paris-
Saclay, 78350 Jouy-en-Josas,
France

Deadline for manuscript
submissions:

closed (31 August 2022)

Message from the Guest Editor

Dear Colleagues,

Recently, the role of the gut microbiota in the pathophysiology of many diseases has been revealed. Particularly, its contribution to cardiometabolic diseases including obesity, diabetes, metabolic syndrome, Non alcoholic fatty liver disease or atherosclerosis is now recognized although the mechanisms involved are still poorly understood. In this context, there is a need for studies including diet, host and the microbiome to decipher how the impairment of the human-microbes symbiosis can lead to the development of these diseases whose incidence is still increasing. This Special issue will include papers on the crosstalk between the gut microbiome, and cardiometabolic diseases and welcomes studies in humans and in preclinical models.

Dr. Philippe Gerard
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPlus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)